We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GW Pharmaceuticals’s Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
GW Pharmaceuticals may be the first drugmaker to roll out a cannabis-based drug in the U.S., but it's unlikely to be the last—and that's why so many are keeping an eye on GW's Epidiolex launch.
UK-based GW Pharmaceuticals and its US division Greenwich Biosciences have launched an oral solution of cannabis-based drug Epidiolex in the US to treat seizures in Lennox-Gastaut syndrome (LGS) or Dravet syndrome patients aged two years and above.